QuidelOrtho Corp 8K

QuidelOrtho Corporation reported Q2 2026 results with modest revenue growth but a GAAP net loss and materially lowered its full-year 2026 revenue, earnings, and free cash flow guidance due to China and respiratory demand headwinds.

On August 6, 2026, QuidelOrtho Corporation reported its unaudited financial results for the second quarter ended June 28, 2026, announcing total revenue of $630.9 million (up 3% reported and 2% constant currency, or 6% excluding China), a GAAP net loss of $92.9 million (loss per share of $1.36), adjusted EBITDA of $129.3 million with a 20.5% margin, and simultaneously revised its full-year 2026 guidance downward—reducing projected total revenues to $2.52–$2.60 billion from $2.70–$2.75 billion, lowering adjusted EBITDA and adjusted EPS ranges, and withdrawing its prior free cash flow guidance—primarily due to demand headwinds in China tied to proposed in vitro diagnostics pricing changes and a softer global respiratory environment.

Filing Facts

CIK

1906324

Ticker

-

Form

8K

Source Type

sec

Accession

0001906324-26-000032

Alert Tier

7